NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $12.28 +1.92 (+18.53%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.30 +0.02 (+0.12%) As of 08/8/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$11.60▼$12.9650-Day Range$9.28▼$12.2852-Week Range$9.20▼$21.48Volume2.06 million shsAverage Volume555,122 shsMarket Capitalization$717.64 millionP/E Ratio13.64Dividend Yield4.89%Price Target$19.00Consensus RatingHold Company Overview Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. Read More Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 95% of companies evaluated by MarketBeat, and ranked 52nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEmbecta has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageEmbecta has only been the subject of 2 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth7.72% Earnings GrowthEarnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 13.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 13.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.76.Price to Earnings Growth RatioEmbecta has a PEG Ratio of 0.67. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.49% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Embecta has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 5.79%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 66.67%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.49% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Embecta has recently decreased by 5.11%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment0.73 News SentimentEmbecta has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Embecta this week, compared to 4 articles on an average week.Search Interest4 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Embecta to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $106,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.42% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News HeadlinesEmbecta Corp. (EMBC) Q3 2025 Earnings Call TranscriptAugust 8 at 3:59 PM | seekingalpha.comEmbecta raises FY25 adjusted EPS view to $2.90-$2.95 from $2.70-$2.90August 8 at 10:57 AM | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)An Overview of Embecta's EarningsAugust 8 at 10:57 AM | benzinga.comEmbecta Corp. Reports Third Quarter Fiscal 2025 Financial ResultsAugust 8 at 6:30 AM | globenewswire.comembecta Announces Quarterly Cash DividendAugust 8 at 6:00 AM | globenewswire.comEmbecta (EMBC) Expected to Announce Earnings on FridayAugust 6 at 4:31 AM | americanbankingnews.comembecta to Report Fiscal Third Quarter 2025 Financial ResultsJuly 24, 2025 | globenewswire.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $20.65 at the start of the year. Since then, EMBC shares have decreased by 40.5% and is now trading at $12.28. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) released its quarterly earnings data on Friday, August, 8th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.77 by $0.35. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. Read the conference call transcript. Who are Embecta's major shareholders? Embecta's top institutional investors include Yacktman Asset Management LP (4.06%), William Blair Investment Management LLC (3.41%), Geode Capital Management LLC (2.59%) and State of Alaska Department of Revenue (0.69%). Insiders that own company stock include Devdatt Kurdikar, David F Melcher, Jacob Elguicze, Jeffrey Z Mann and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Record date for 6/13 Dividend5/28/2025Ex-Dividend for 6/13 Dividend5/28/2025Dividend Payable6/13/2025Today8/08/2025Last Earnings8/08/2025Next Earnings (Estimated)8/08/2025Record date for 9/15 Dividend8/29/2025Dividend Payable9/15/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,100Year FoundedN/APrice Target and Rating Average Price Target for Embecta$19.00 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+54.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio13.64 Forward P/E Ratio4.31 P/E Growth0.63Net Income$78.30 million Net Margins4.89% Pretax Margin5.10% Return on Equity-19.67% Return on Assets12.27% Debt Debt-to-Equity RatioN/A Current Ratio2.48 Quick Ratio1.83 Sales & Book Value Annual Sales$1.08 billion Price / Sales0.66 Cash Flow$4.15 per share Price / Cash Flow2.96 Book Value($12.80) per share Price / Book-0.96Miscellaneous Outstanding Shares58,443,000Free Float58,198,000Market Cap$717.68 million OptionableOptionable Beta1.08 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:EMBC) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.